CD274 and neoplasm: Unlike traditional cytotoxic regimens—such as chemotherapy and radiation—that directly target rapidly dividing tumour cells, immune checkpoint inhibitors (ICIs) represent monoclonal antibodies designed to antagonize inhibitory pathways involving PD-1, PD-L1, or CTLA-4 [4,5].